←
Neil Rodrigues562 posts
Neil Rodrigues avatar

Neil Rodrigues

@NRodriguesLab

Reader @cardiffuni. PhD @MRC_MHU @greentempleton @UniofOxford. Former Assistant Professor at @BUMedicine. My lab mission is to #beatbloodcancer.

◷ Joined July 2019▧ 1 Photos and videos
Neil Rodrigues avatar
Neil Rodrigues@NRodriguesLab·Feb 6

In #HeartMonth and on #WearRedDay I am pleased to announce a new PhD studentship in my lab to study and develop novel therapies to target cardiovascular disease development, application deadline March 6 for a October 2026 start, please RX: eur03.safelinks.protection.o…

Caroline Watson avatar
⟳ Neil Rodrigues retweeted
Caroline Watson@carolinewatson·Nov 11

How does leukaemia develop? 🩸 How long does it take? ⏳ 🌟 Our paper, started back when I was a PhD student in @jrblundell’s lab, is out today in @Nature 🌟 Yearly blood samples from women who developed AML in later life let us trace it back decades 👇 doi.org/10.1038/s41586-026-1…

1:57
Hematopoiesis News avatar
⟳ Neil Rodrigues retweeted
Hematopoiesis News@Hema_News·Sep 22

Menin inhibitors like revumenib and ziftomenib show high initial response rates in AML, but durability remains limited due to on-target mutations, off-target clonal evolution, and epigenetic escape. Next-generation combination strategies in the frontline setting may help minimize clonal escape. 📗 Read the full review: bit.ly/4xDEjIM Research by Abdulrahman Alhajahjeh, Maximilian Stahl, Amer M. Zeidan and Jan Philipp Bewersdorf at @YaleMed. Image credit: Makysm - Own work, CC0, bit.ly/4ye9k7o #AML #Leukemia #Oncology

Post attachment
NEJM avatar
⟳ Neil Rodrigues retweeted
NEJM@NEJM·Sep 7

In a phase 2, randomized trial, azacitidine–venetoclax therapy led to significantly longer event-free survival than induction chemotherapy among induction-eligible patients with AML. Full PARADIGM Research Summary: nej.md/4zJr1wV

Post attachment
Alex Tonks avatar
⟳ Neil Rodrigues retweeted
Alex Tonks@alex_tonks·Aug 15

A wonderful evening is planned at the @bloodcancer_uk Charity Ball. Organised by Nicola and support by Rhia (@RhiaStankovic and @BloodCUK_Wales ) to raise funds to support blood cancer research. Nicola has done an amazing job and we are kicking off with a very nice garden party!

Post attachmentPost attachmentPost attachmentPost attachment
Kamil R Kranc avatar
⟳ Neil Rodrigues retweeted
Kamil R Kranc@kamilkranc·Aug 13

Delighted to see our new paper out today in Science Advances! We identify TUT4/7 as therapeutic targets in AML: their deletion or inhibition compromises AML while largely sparing normal haematopoiesis. Thanks to our collaborators & @CR_UK! science.org/doi/10.1126/scia…

Our latest paper on targeting TUT4/7 in acute myeloid leukaemia went live at 7PM, coinciding perfectly with the eclipse. A hike from work to watch and celebrate. More to follow tomorrow, thanks to everyone who contributed, @kamilkranc , @CarrollDonal and many, many others.

Post attachmentPost attachment
Jennifer Trowbridge avatar
⟳ Neil Rodrigues retweeted
Jennifer Trowbridge@TrowbridgeLab·Aug 1

📢 BIG NEWS in ISEH's journal Experimental Hematology!!! 2 new article types specifically designed for research often difficult to publish: validated protocols, null results, phenotyping & high-value datasets. Plus fast-track review + a $650 incentive! 🔗 iseh.org/Publications/ExpHem…

📢 Experimental Hematology, the official journal of ISEH, has launched new article types and author incentives! View the latest updates and submit your next manuscript: iseh.org/Publications/ExpHem…

Post attachment
Jennifer Trowbridge avatar
⟳ Neil Rodrigues retweeted
Jennifer Trowbridge@TrowbridgeLab·Aug 6

New work from our lab out today in @NatureCellBio led by @jaynathemistry!! nature.com/articles/s41556-0… 🧵 on how clonal hematopoiesis turns the bone marrow niche into an accomplice:

Hematopoiesis News avatar
⟳ Neil Rodrigues retweeted
Hematopoiesis News@Hema_News·Jul 30

Investigators introduce a clonal #hematopoietic stem and progenitor cell (HSPC) tracker, an in vitro framework for serially tracking clonal differentiation and fate acquisition from human HSPCs extracted from circulation. bit.ly/45umZdH

Post attachment
Parham Habibzadeh avatar
⟳ Neil Rodrigues retweeted
Parham Habibzadeh@HabibzadehMD·Jun 26

Biological aging is accelerating in recent generations and it’s linked to the rise in early-onset cancers @NatureMedicine. In UK Biobank (154k young adults): 1⃣PhenoAge “age gap” ↑ 23% s.d. in people born 1965–74 vs 1950–54 2⃣Each s.d. higher age gap → 8% higher risk of early-onset solid cancers (HR 1.08) 3⃣Strongest for lung (HR 1.57), GI/colorectal, and uterine cancers A new integrative lens on why early-onset cancers are rising and potential prevention targets. nature.com/articles/s41591-0… #EarlyOnsetCancer #BiologicalAging #CancerResearch #AgingResearch #CancerPrevention #PhenoAge

Post attachmentPost attachmentPost attachment
Alhomidi Almotiri د.الحميدي بن حوكه avatar
⟳ Neil Rodrigues retweeted
Alhomidi Almotiri د.الحميدي بن حوكه@abosalem_Motiri·Jun 28

Thrilled to announce that my review paper has been published in Aging and Disease. This work explored how the metabolism of hematopoietic stem cells (HSCs) changes with age, and how leukemic stem cells (LSCs) exploit similar metabolic pathways to survive and resist therapy. I compared the metabolic programs — glycolysis, mitochondrial OXPHOS, and amino acid and lipid metabolism — of young HSCs, aged HSCs, and LSCs, while also addressing the clinical opportunities and challenges of targeting these vulnerabilities: rejuvenating aged HSCs without driving clonal expansion, and selectively eliminating LSCs while sparing healthy hematopoiesis. It’s incredibly rewarding to contribute to this rapidly evolving field and to envision how a deeper understanding of stem cell metabolism could one day translate into therapies for aging-related blood disorders and leukemia. eur04.safelinks.protection.o… #Aging #StemCellMetabolism #Leukemia